This site is fictional demo content. It is not real news or affiliated with any real organization. Do not treat it as fact or professional advice.

NextPaper Logo
nextpaper.ccCYBER CHRONICLE
RSS
EN中文

Full article

FULL TEXT

View this issue
HeadlineMEDTECH

Brain-Computer Interface for Treatment-Resistant Depression Receives FDA Breakthrough Device Designation: NeuroPace RNS System Upgrade Shows 68% Efficacy

NeuroPace's closed-loop brain-computer interface system DeepFocus received FDA Breakthrough Device designation, achieving 68% clinical response rate in treatment-resistant depression patients through real-time monitoring of mood-related neural circuits and precise electrical stimulation.

On April 4, 2028, NeuroPace announced that its closed-loop brain-computer interface system DeepFocus received FDA Breakthrough Device designation. Designed specifically for treatment-resistant depression patients who have failed to respond to at least two medications and psychotherapy, the system uses implanted electrodes to monitor neural activity patterns in the medial prefrontal cortex and amygdala in real-time, automatically delivering millisecond-precision electrical stimulation to restore normal neural circuit function when depression-related abnormal neural oscillations are detected.

In the pivotal clinical trial, 120 treatment-resistant depression patients received DeepFocus implants and were followed for 12 months. 68% achieved clinical response criteria (50% or greater reduction in Hamilton Depression Rating Scale scores), and 42% achieved full remission. Unlike traditional deep brain stimulation (DBS) "open-loop" mode, DeepFocus only triggers stimulation when abnormal neural activity is detected, with average daily stimulation time not exceeding 15 minutes, significantly reducing side effects and battery consumption.

UCSF neurosurgery chief Edward Chang, the trial's principal investigator, stated that DeepFocus represents a paradigm shift in neuropsychiatric treatment from "blind stimulation" to "precision modulation." "We're no longer applying continuous stimulation to entire brain regions — instead, we intervene precisely when needed, like adjusting a thermostat."

However, the ethical boundaries of BCI treatment for mental illness have sparked widespread debate. Columbia University bioethics professor Joseph Fins noted that directly intervening in brain emotional circuits may affect patients' personality traits and autonomous decision-making capacity, and the line between "curing" and "changing a person" requires careful delineation. NeuroPace responded that all DeepFocus stimulation parameters are jointly set by patients and physicians, and patients can pause or adjust the system at any time through an external controller.

DeepFocus surgery costs approximately $80,000, with total treatment costs including equipment and follow-up around $120,000. NeuroPace is negotiating insurance coverage with major US insurers.